Hutchinson-Gilford Progeria Syndrome (HGPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Hutchinson-Gilford Progeria Syndrome (HGPS) is a genetic condition that causes ageing to appear suddenly and dramatically in childhood. Affected children appear normal at birth and early childhood but grow more slowly than other children and do not gain weight at the expected rate (failure to thrive). Mutations in the LMNA gene cause Hutchinson-Gilford progeria syndrome. The LMNA gene provides instructions for making a protein known as lamin A.
·
The prevalence of Hutchinson-Gilford Progeria
Syndrome (HGPS) is approximately 1 in 20 million, so at any given time,
approximately 400 children are living with progeria worldwide. As of December
2020, the Progeria Research Foundation International Progeria Registry has
identified a total of 131 children and young adults living with progeria
worldwide, including 20 living in the US.
Thelansis’s “Hutchinson-Gilford
Progeria Syndrome (HGPS) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Hutchinson-Gilford
Progeria Syndrome (HGPS) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Hutchinson-Gilford Progeria Syndrome (HGPS) across the 8 MM market from the
centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Hutchinson-Gilford Progeria Syndrome
(HGPS) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard),
which Data Inputs with sourcing, Market Event, and Product Event, Country
specific Forecast Model, Market uptake and patient share uptake, Attribute
Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and
Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment